ARTICLE | Product Development
PPL's positive view
March 1, 1999 8:00 AM UTC
PPL Therapeutics plc reported "positive" Phase IIc results for its transgenically produced alpha-1-antitrypsin (AAT) to treat cystic fibrosis. While skeptics might find that the results -- which were not significant -- were hardly positive, the company argues that the data may point it towards a more definitive, adequately powered trial design...